Comorbidity of sickle cell trait and albinism: a cross-sectional survey in the Democratic Republic of the Congo

Paul Kambale-Kombi, Roland Marini Djang´eing´a, Jean-Pierre Alworong´a Opara, Gaylor Inena wa Inena, Daddy Falay Sadiki, François Boemer, Vincent Bours, Charles Kayembe Tshilumba, Salomon Batina Agasa

Corresponding author: Paul Kambale-Kombi, Département de Médecine Interne, Cliniques Universitaires de Kisangani, Faculté de Médecine et de Pharmacie, Université de Kisangani, République Démocratique du Congo

Received: 27 Nov 2019 - Accepted: 19 Feb 2020 - Published: 17 Apr 2020

Domain: Internal medicine

Keywords: Comorbidity, sickle cell trait, albinism, Democratic Republic of the Congo

© Paul Kambale-Kombi et al Pan Africa Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Paul Kambale-Kombi et al. Comorbidity of sickle cell trait and albinism: a cross-sectional survey in the Democratic Republic of the Congo. Pan Africa Medical Journal. 2020;35:127. [doi: 10.11604/pamj.2020.35.127.21113]

Available online at: https://www.panafrican-med-journal.com/content/article/35/127/full

Research

Comorbidity of sickle cell trait and albinism: a cross-sectional survey in the Democratic Republic of the Congo

Paul Kambale-Kombi1,8, Roland Marini Djang’eing’a2, Jean-Pierre Alworong’a Opara3, Gaylor Inena wa Inena4, Daddy Falay Sadiki3, François Boemer5, Vincent Bours5, Charles Kayembe Tshilumba1, Salomon Batina Agasa1

1Département de Médecine Interne, Cliniques Universitaires de Kisangani, Faculté de Médecine et de Pharmacie, Université de Kisangani, République Démocratique du Congo, 2Département de Pharmacie, Chimie Analytique Pharmaceutique, CHU de Liège, Faculté de Médecine, Université de Liège, Belgique, 3Département de Pédiatrie, Cliniques Universitaires de Kisangani, Faculté de
**Abstract**

**Introduction:** Sickle Cell Disease (SCD) and albinism are both recessive hereditary diseases in humans with a high prevalence in sub-Saharan Africa. This study aimed to determine the prevalence of sickle cell trait in people living with albinism (PLA).

**Methods:** A cross-sectional descriptive survey was conducted in PLA attending the "Hôpital du Cinquantenaire de Kisangani". In total, by non-probabilistic convenience sampling, 82 albinos and 139 non-albino subjects and without antecedents of albinism were included, selected from students in the Faculty of Medicine and Pharmacy at the University of Kisangani. Blood samples were collected on "dried blood spot" and analysed by mass spectrometry at CHU of Liège. Data were entered into an Excel file and analysed on SPSS 20.0 (Chicago, IL).

**Results:** Forty-six of the 82 albinos (56.1%) were female and 43.9% male with a sex ratio of 1.28. Among albinos, 18.3% had hemoglobin AS (HbAS) and 81.7% hemoglobin AA (HbAA) compared to 18% of subjects with hemoglobin AS and 82% hemoglobin AA in the control group. The difference was not statistically significant (Chi-square=0.003, ddl=1, p=0.9544).

**Conclusion:** This study highlighted that the prevalence of the sickle cell trait is high among people living with albinism, but does not differ from that observed in non-albinos in the Democratic Republic of the Congo. It is therefore important to raise awareness among this category of people about sickle cell disease and the importance of its premarital screening.

---

**Introduction**

Sickle cell anemia and albinism are both recessive hereditary diseases in humans with a high prevalence in sub-Saharan Africa populations [1]. Today’s, sickle cell disease (SCD) is the most common genetic disease worldwide. The annual number of newborns with sickle cell disease was estimated to be 305 800 (CI: 238 400–398 800) in 2010 with 79% (242 200 [CI: 194 500 (82%)-302 000 (76%)]) occurring in sub-Saharan Africa [2]. SCD is an autosomal recessive genetic disease, except in rare forms such as HbSAntilles and HbSOMan, due to a mutation at the 6th codon of the β-globin gene that leads to the replacement of adenine by thymine (GAG→GTG). As a result, glutamic acid is replaced by valine at the sixth position of β-globin on chromosome 11, leading to the
formation of sickle red blood cells (RBC) containing abnormal hemoglobin (HbS: α2βS2), rather than normal adult hemoglobin (HbA: α2βS2) [3].

The polymerization of this abnormal hemoglobin (HbS) under certain conditions such as deoxygenated conditions, makes the sickle red blood cell fragile and less deformable, responsible of the clinical features of the disease. Albinism includes a heterogeneous group of genetic abnormalities that affect 1 in 20,000 individuals worldwide [4]. It is characterized by a reduced or lack of melanin production leading to hypopigmentation of the skin, hair and eyes. Generally, three forms of albinism are distinguished: ocular albinism (OA) which is a X-linked inherited disease related to gene GPR 143, oculocutaneous albinism (OCA) which is an autosomal recessive inherited disease and syndromic forms [5]. Seven subtypes of oculocutaneous albinism have been described. However, four subtypes are better characterized and the genes involved are: TYR on chromosome 11q14 for OCA 1, OCA 2 (P) for OCA 2, TYRP1 for OCA 3 and SLC45A2 (MATP) for OCA 4. The syndromic forms include Hermansky-Pudlak syndrome, related to the HPS-1 gene and Chediak-Higashi syndrome, related to the CHS-1 gene [4,6-11].

It has been estimated that albinism affects 1 in 20000 people worldwide and in Africa, with incidences ranging from 1 in 2700 to 1 in 10000 people [6]. Oculocutaneous albinism is the most common in sub-Saharan Africa with estimated prevalences of 1 in 1755 in Namibia, 1 in 2675 in Tanzania, 1 in 4728 in Zimbabwe and 1 in 3900 in South Africa. The overall prevalence of albinism in sub-Saharan Africa is estimated at 1 in 2000-5000 [7,8,12,13]. Oculocutaneous albinism, which is an autosomal recessive hereditary disease had been documented to co-exist with abnormal hemoglobin conditions like sickle cell disease [1]. But surveys that have focused on this comorbidity are scarce in sub-Saharan Africa and the two studies that reported this observation, each involved only one albino family [14,15]. In the DRC, albinism is known to be widespread even if to date, there have been no prevalence studies. Similarly, the prevalence of sickle cell disease is high at about 1.4% for the homozygous form [16] and 23.3% for the heterozygous form [17].

In addition, WHO estimates that the AS carrier rate is 25% and the annual incidence of the homozygous SS form around 15% births in the DRC [18], which is one of the three most affected countries by SCD worldwide [2]. However, to our knowledge, no studies evaluating the comorbidity of these two diseases have not yet been conducted. This study aimed to determine the prevalence of sickle cell trait in people living with albinism in Kisangani (northeastern of Democratic Republic of the Congo).

**Methods**

We conducted a cross-sectional descriptive survey in PLA attending the “Hôpital du Cinquantenaire de Kisangani” from the 30th July to the 6th September 2019, as well as students in the Faculty of Medicine and Pharmacy at the University of Kisangani at the same period. In total, by non-probabilistic convenience sampling, we included 82 albino and 139 non-albino subjects who constituted the control group. A total of 121 albinos visited the facility during the study period, but only 82 subjects who provided written consent or
parental written consent for children, were included in the survey. Of all the students present at the time of the survey, 157 had willingness to provide written consent, but only 139 were included based on the inclusion criteria that were: not to be an albino and not having the history of albinism in the family. For haemoglobin phenotyping, blood samples were collected on "dried blood spot" (DBS) by capillary puncture and the analysis was performed by mass spectrometry at the Biochemical Genetics Laboratory of CHU of Liège. Data were entered into an Excel file and analysed on SPSS 20.0 (Chicago, IL). In addition, the data were summarized in form of proportions and frequency tables for categorical variables. Continuous variables were summarized using means, median and standard deviation. P-value was computed for categorical variables using Chi-square ($\chi^2$) test. A p-value of less than 0.05 was considered to constitute a statistically significant difference.

Results

Of the 221 subjects studied, 82 (37.1%) were albinos ranging in age from 1.6 to 48 years. Their mean age was 18.3±11.37 years and the median age was 17 years. The control group consisted of 139 non albino subjects (62.9%) with no albinism family history. Their mean age was 26.9±8.19 years and the median age was 25.5 years. Forty-six (56.1%) of the 82 albinos were female and 43.9% male with a sex ratio of 1.28 (Table 1). Among albinos, 18.3% had AS hemoglobin (HbAS) and 81.7% hemoglobin AA (HbAA) compared to 18% of subjects with hemoglobin AS and 82% hemoglobin AA in the control group. The difference was not statistically significant (Chi-square = 0.003, ddl=1, p=0.9544) (Table 2).

Discussion

In this study, among albinos, females represented 56.1% (Table 1) with a female to male ratio of 1.28; 18.3% had hemoglobin AS (HbAS) and 81.7% hemoglobin AA (HbAA) compared to 18% of subjects with hemoglobin AS and 82% hemoglobin AA in the control group but with no statistically significant difference (p-value >0.05) (Table 2). Similar to what we found in this work, Marçon CR et al. (2019), Emadi SE et al. (2017) and Yang et al. (2019) reported that most of the PLA were females, respectively 57.07%, 52.9% and 58.3% [9,19,20]. The same observation emerges from the studies by Massie RW and Hartmann RC (1957) and Aquaron R et al. (2007) [14,15]. In a most recent study conducted in Kinshasa on 200 albinos, Kakiesse V et al. reported the same finding with a sex ratio of 1.08 in favor of females [21]. However, the reason for this sex difference remains unclear. Hence, more studies are needed to elucidate this observation. Although albinism is an autosomal recessive genetic disease, such as sickle cell disease, at least for the oculocutaneous form, to date, there is no formal evidence of a link between these two diseases.

Nevertheless, some observations suggested their possible association. Indeed, the first study that focused on the albinism and sickle cell disease association dates back to the 1950’s and was aroused by the observation of Massie RW and Hartmann RC in an
African-American family with 4 albino children. One of them had the homozygous form of sickle cell disease and the other three had the sickle cell trait. Their study excluded an absolute linkage between sickle cell disease and albinism but claimed that a looser linkage was possible [14]. Later (2007), Aquaron R et al. reported, in the Ewondo ethnic group in Cameroon, a family of children presenting both albinism and sickle cell disease. In all three cases, it was Oculocutaneous albinism type 2 (OCA2) with a homozygous 2.7-kb deletion of the P gene. In one case, oculocutaneous albinism type 2 (OCA2) was associated with the homozygous form of sickle cell disease and in the other two cases, AOC2 was associated with the sickle cell trait. However, the study remained silent on a possible link between the two diseases [15].

In a more recent study, on the basis of empirical observation that light-skinned sickle-cells patients tend to have less severe phenotypic expression of the disease when compared to those with darker skin color, Muideen et al. postulated the hypothesis that hypermelanotic or hypomelanotic skin status of homozygous SCD patient would influence the severity of the SCD phenotypic expression [1]. Our findings are therefore in agreement with that of Massie RW and Hartmann RC and indicates that the prevalence of sickle cell trait is not higher in albinos compared to non-albinos, since we did not observe a statistically significant difference between albinos and the control group (p=0.95). These results are not surprising as there is not any direct linkage between the albinism genes and the HbB gene. Moreover, our data suggest that the prevalence of sickle cell trait observed among albinos (18.3%) is similar to that expected in the general Congolese population. Indeed, Batina et al. reported the prevalence of 23.3% of the sickle cell trait in newborns in Kisangani (DRC) compared to about 1% for the homozygous form [17]. Similarly, Tshilolo et al. in Kinshasa observed a neonatal prevalence of sickle cell disease of 16.9% for the sickle cell trait and 1.4% for the homozygous form [16].

Conclusion

Our results show that the prevalence of the sickle cell trait is high among people living with albinism, but does not differ from that observed in non-albinos in the Democratic Republic of the Congo. It is therefore important to raise awareness among people living with albinism about sickle cell disease and the importance of its premarital screening, as well as the general population.

Study limitations: the relatively small number of albinos is a limitation of this study. The same applies to the selection of the control group made by convenience sampling. Nevertheless, this study contributes to the improvement of knowledge on the comorbidity sickle cell disease and albinism.

What is known about this topic

- It has been suggested that there is no absolute linkage between sickle cell disease and albinism, but that a looser linkage was possible.

What this study adds

- This study provides data on the comorbidity of Sickle cell disease
and albinism in sub-Saharan Africa; it also provides arguments that the prevalence of the sickle cell trait is not higher in people living with albinism, especially in the Democratic Republic of the Congo.

Competing interests

The authors declare no competing interests.

Authors’ contributions

Kambale Kombi Paul designed the study, developed the protocol, collected and analysed the data and wrote the article. Batina Agasa Salomon participated in the design of the study, the development of the protocol and in the drafting the manuscript. Marini Djiang’eing’a Roland and Alworong’a Jean-Pierre participated in developing the protocol and in the revision of the manuscript. Boemer François and Bours Vincent have carried out laboratory tests. They also analysed the data and participated in the revision of the manuscript. Falay Sadiki Daddy and Inena wa Inena Gaylor participated in the collection of data and in the revision of the manuscript. Kayembe Tshilumba Charles participated in the design of the study and final writing of the manuscript. All the authors have read and agreed to the final manuscript.

Acknowledgments

The authors acknowledge the responsibles of the «Hôpital du Cinquantenaire de Kisangani» and the non-governmental organization «Corbetta RDC» for facilitating the data collection. They also acknowledge the student Toussaint Agambu Kilandja and Mr. LEDUC Stéphane for their participation in the data collection and in laboratory tests respectively. Finally, the authors would like to thank the Belgian Académie de Recherche et d’Enseignement Supérieur (ARES) particularly, for the PhD scholarship.

Tables

Table 1: characteristics of the participants

Table 2: phenotype of hemoglobin

References

1. Bakare MO. Severity in phenotypic expression of homozygous sickle cell disease (Hb.SS)-does hypermelanotic or hypomelanotic skin status of affected patients play a role. Med Hypotheses. 2011;76(5):673-5. PubMed | Google Scholar

2. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global
burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality and interventions. PLoS Med. 2013;10(7):e1001484. PubMed | Google Scholar

3. Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710-1719. PubMed | Google Scholar

4. Khordadpoor-Deilamani F, Akbari MT, Karimipoor M, Javadi G. Sequence analysis of tyrosinase gene in ocular and oculocutaneous albinism patients: introducing three novel mutations. Mol Vis. 2015;21:730-735. PubMed | Google Scholar

5. Arveiler B, Lasseaux E, Morice-Picard F. Clinical and genetic aspects of albinism. Presse Med. 2017;46(7-8 Pt 1):648-654. PubMed | Google Scholar

6. Mabula JB, Chalya PL, Mchembe MD, Jaka H, Giiti G, Rambau P et al. Skin cancers among albinos at a University teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases. BMC Dermatol. 2012;12:5. PubMed | Google Scholar

7. Hong ES, Zeeb H, Repacholi MH. Albinism in Africa as a public health issue. BMC Public Health. 2006;6:212. PubMed | Google Scholar

8. Bradbury-Jones C, Ogik P, Betts J, Taylor J, Lund P. Beliefs about people with albinism in Uganda: a qualitative study using the Common-Sense Model. PLoS One. 2018;13(10):e0205774. PubMed | Google Scholar

9. Yang Q, Yi S, Li M, Xie B, Luo J, Wang J et al. Genetic analyses of oculocutaneous albinism types 1 and 2 with four novel mutations. BMC Med Genet. 2019;20(1):106. PubMed | Google Scholar

10. Lund PM, Gaigher R. A health intervention programme for children with albinism at a special school in South Africa. Health Education Research. 2002;17(3),365-372. PubMed | Google Scholar

11. Lund P, Roberts M. Prevalence and population genetics of albinism: surveys in Zimbabwe, Namibia and Tanzania: chapter 4 in: Kromberg J & Manga P (Eds) albinism in Africa: historical, geographical, medical, genetic and psychosocial aspects. Elsevier. 2018. Google Scholar

12. Massie RW, Hartmann RC. Albinism and sicklemia in a Negro
family. Am J Hum Genet. 1957;9(2):127-32. PubMed | Google Scholar

15. Aquaron R, Soufir N, Berge-Lefranc J, Badens C, Austerlitz F, Grandchamp B. Oculocutaneous albinism type 2 (OCA2) with homozygous 2.7-kb deletion of the P gene and sickle cell disease in a Cameroonian family: identification of a common TAG haplotype in the mutated P gene. J Hum Genet. 2007;52(9):771-80. PubMed | Google Scholar

16. Tshilolo L, Aissi LM, Lukusa D, Kinsiami C, Wembonyama S, Gulbis B et al. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin Pathol. 2009;62(1):35-8. PubMed | Google Scholar

17. Agasa B, Bosunga K, Opara A, Tshilumba K, Dupont E, Vertongen F et al. Prevalence of sickle cell disease in a northeastern region of the Democratic Republic of Congo: what impact on transfusion policy. Transfus Med. 2010;20(1):62-5. PubMed | Google Scholar

18. Shongo MYP, Mukuku O, Lubala TK, Mutombo AM, Kanteng GW, Umumbu WS et al. Drépanocytose chez l'enfant lushois de 6 à 59 mois en phase stationnaire: épidémiologie et Clinique. Pan African Medical Journal. 2014;19:71. PubMed | Google Scholar

19. Marçon CR, Moraes JC, de Olivas Ferreira MAM, Oliari CB. Dermatological and epidemiological profiles of patients with albinism in São Paulo, Brazil, between 2010 and 2017: a cross-sectional study. Dermatology. 2019;28:1-9. PubMed | Google Scholar

20. Emadi SE, Juma Suleh A, Babamahmoodi F, Ahangarkani F, Betty Chelimo V, Mutai B et al. Common malignant cutaneous conditions among albinos in Kenya. Med J Islam Repub Iran. 2017;31:3. PubMed | Google Scholar

21. Kakiesse V, Iteke M, Nkwembe R, Mayuba J, Tshilombo JM, Kayembe JM. Lésions cutanées observées dans l'albinisme oculocutané: résultats d'une campagne de dépistage dans la ville-province de Kinshasa. Annales de Dermatologie et de Vénéréologie. 2018;145(4,Supplement):A40. Google Scholar
PAMJ Services
Pan African Medical Journal
PAMJ Conference Proceedings
PAMJ Conference Management System
PAMJ Clinical Medicine
PAMJ Supplements

For authors
Copyright agreements
Editorial policy
Instructions for authors
PAMJ - authors services

About PAMJ - Manuscript Hut™
The Manuscript Hut is a product of the PAMJ Center for Public health Research and Information.

Kenya: 3rd Floor, Park Suite Building, Parkland Road, Nairobi. PoBox 38583-00100, tel: +254 (0)20-520-4356

Cameroon: Immeuble TechnoPark Essos, Yaounde, PoBox: 10020 Yaounde, tel: +237 (0)24-309-5880

Copyright © - Pan African Medical Journal - CEPHRI. 2020

Haraka Publishing Platform - (MMS V.2.5). Release date Jan 2018 - Customized for The Pan African Medical Journal

services@panafrican-med-journal.com